Control of SIV Rebound Through Structured Treatment Interruptions During Early Infection
- 24 November 2000
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 290 (5496) , 1591-1593
- https://doi.org/10.1126/science.290.5496.1591
Abstract
In a randomized controlled trial with acute simian immunodeficiency virus (SIV)–infected macaques, both highly active antiretroviral therapy (HAART) and HAART with fixed-schedule structured treatment interruption (STI-HAART; alternating 3 weeks on and 3 weeks off therapy) suppressed viral load. In the STI-HAART group, T cell virus-specific immune response (VIR) and control of viral rebound increased concurrently during subsequent interruptions. In contrast, VIR did not increase and SIV rebounded after permanent treatment withdrawal in all animals on continuous HAART. Fixed-schedule STI-HAART appears to be an effective alternative to continuous HAART for the early treatment of retroviral infection.Keywords
This publication has 19 references indexed in Scilit:
- HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapyJournal of Clinical Investigation, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Control of HIV despite the Discontinuation of Antiretroviral TherapyNew England Journal of Medicine, 1999
- Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNAScience, 1998
- Plasma SIV RNA Viral Load Determination by Real-Time Quantification of Product Generation in Reverse Transcriptase-Polymerase Chain ReactionAIDS Research and Human Retroviruses, 1998
- Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.The Journal of Experimental Medicine, 1995
- Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 InfectionNew England Journal of Medicine, 1995
- Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 ReplicationScience, 1994
- Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compoundsThe Lancet, 1994
- Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.Proceedings of the National Academy of Sciences, 1993